E7070 (Not yet branded)
Other Medications
Description
E7070 (indisulam) is a cyclin-dependent kinase inhibitor that has been evaluated in combination regimens for metastatic colorectal cancer. This compound belongs to the class of cell cycle inhibitors that target specific phases of cellular division. In colorectal cancer treatment, E7070 has been combined with standard chemotherapy agents including capecitabine and irinotecan to enhance antitumor efficacy in patients with advanced disease.
Mechanism of Action
E7070 works by inhibiting cyclin-dependent kinases, particularly CDK2 and CDK4, which are essential enzymes that regulate cell cycle progression from G1 to S phase. By blocking these kinases, the drug prevents cancer cells from completing DNA synthesis and cell division, leading to cell cycle arrest and subsequent apoptosis.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.